Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 14;72(5):1209–1224. doi: 10.1007/s00262-022-03312-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Reconstitution of Vδ1 and Vδ2 γδ T cells in CML patients during the TKI therapy. CML patients were divided at diagnosis into imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4) cohorts. Absolute numbers of Vδ1 (A) and Vδ2 (B) and frequencies of Vδ1 (C) and Vδ2 (D) γδ T cells in patients on imatinib compared to HD (n = 40) were determined at diagnosis (CML dg.) during the 18 months therapy as 3 months (CML + 3), 6 months (CML + 6), 12 months (CML + 12) and 18 months (CML + 18). Similarly, Vδ1 (E) and Vδ2 (F) γδ T cells and frequencies of Vδ1 (G) and Vδ2 (H) γδ T cells in patients on nilotinib were analyzed. Finally, absolute counts of Vδ1 (I) and Vδ2 (J) γδ T cells and frequencies of Vδ1 (K) and Vδ2 (L) γδ T cells on dasatinib (n = 4) are presented. The median values are shown. Statistically significant differences are presented as **** p < 0.0001, ** p < 0.001 and * p < 0.01

Fig. 3 — Reconstitution of Vδ1 and Vδ2 γδ T cells in CML patients during the TKI therapy. CML patients were divided at diagnosis into imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4) cohorts. Absolute numbers of Vδ1 (A) and Vδ2 (B) and frequencies of Vδ1 (C) and Vδ2 (D) γδ T cells in patients on imatinib compared to HD (n = 40) were determined at diagnosis (CML dg.) during the 18 months therapy as 3 months (CML + 3), 6 months (CML + 6), 12 months (CML + 12) and 18 months (CML + 18). Similarly, Vδ1 (E) and Vδ2 (F) γδ T cells and frequencies of Vδ1 (G) and Vδ2 (H) γδ T cells in patients on nilotinib were analyzed. Finally, absolute counts of Vδ1 (I) and Vδ2 (J) γδ T cells and frequencies of Vδ1 (K) and Vδ2 (L) γδ T cells on dasatinib (n = 4) are presented. The median values are shown. Statistically significant differences are presented as **** p < 0.0001, ** p < 0.001 and * p < 0.01